ESMO 2025 | Assessing the role of metronomic regimens in head and neck cancers
Marcelo Bonomi, MD, The Ohio State University, Columbus, OH, comments on the current feasibility of metronomic chemotherapy and cemiplimab for head and neck cancer, noting its clear advantage in the recurrent metastatic setting with a high response rate and improved survival when adding low-dose chemotherapy to immunotherapy. This regimen is now being studied in the early stages of the disease, particularly in newly diagnosed patients with head and neck cancer, although this research is still in its initial phases. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
At this point, we’re still studying this regimen in the recurrent metastatic setting, basically patients who relapse after treatment with radiation, radiation chemotherapy or surgery followed by chemoradiation. In this setting, we’re seeing that there’s a clear advantage of adding this very tolerable low-dose regimen of chemotherapy to immunotherapy because patients, we see that they have a high response rate and they live longer...
At this point, we’re still studying this regimen in the recurrent metastatic setting, basically patients who relapse after treatment with radiation, radiation chemotherapy or surgery followed by chemoradiation. In this setting, we’re seeing that there’s a clear advantage of adding this very tolerable low-dose regimen of chemotherapy to immunotherapy because patients, we see that they have a high response rate and they live longer. We’re starting to study this regimen in the early stages, especially when we come across newly diagnosed head and neck cancer, but that is research that is just starting.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
